Table 1:
Baseline demographics and clinical characteristics
| Full study cohort | RNA-Seq cohort | |||
|---|---|---|---|---|
| Nivolumab | Nivo + Ipi | Nivolumab | Nivo + Ipi | |
| N | 245 | 215 | 156 | 130 |
| STAGE | ||||
| Extensive | 186 (76%) | 159 (74%) | 121 (78%) | 100 (77%) |
| Limited | 59 (24%) | 56 (26%) | 35 (22%) | 30 (23%) |
| AGE | ||||
| < 65 | 137 (56%) | 114 (53%) | 86 (55%) | 71 (55%) |
| ≥ 65 | 108 (44%) | 101 (47%) | 70 (45%) | 59 (45%) |
| REGION | ||||
| US | 151 (62%) | 124 (58%) | 102 (65%) | 82 (63%) |
| Rest of World | 94 (38%) | 91 (42%) | 54 (35%) | 48 (37%) |
| FIRST-LINE PLATINUM SENSITIVITY | ||||
| Platinum-resistant | 109 (45%) | 94 (44%) | 77 (49%) | 59 (45%) |
| Platinum-sensitive | 134 (55%) | 115 (54%) | 77 (49%) | 69 (53%) |
| Unknown | 2 (1%) | 6 (3%) | 2 (1%) | 2 (2%) |
| CNS METASTASES | ||||
| No | 224 (91%) | 196 (91%) | 145 (93%) | 114 (88%) |
| Yes | 21 (9%) | 19 (9%) | 11 (7%) | 16 (12%) |